These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 27651098)
1. Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV. Poppova L; Janovska P; Plevova K; Radova L; Plesingerova H; Borsky M; Kotaskova J; Kantorova B; Hlozkova M; Figulova J; Brychtova Y; Machalova M; Urik M; Doubek M; Kozubik A; Pospisilova S; Pavlova S; Bryja V Br J Haematol; 2016 Dec; 175(5):851-859. PubMed ID: 27651098 [TBL] [Abstract][Full Text] [Related]
2. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Lu D; Zhao Y; Tawatao R; Cottam HB; Sen M; Leoni LM; Kipps TJ; Corr M; Carson DA Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3118-23. PubMed ID: 14973184 [TBL] [Abstract][Full Text] [Related]
3. Methylprednisolone suppresses the Wnt signaling pathway in chronic lymphocytic leukemia cell line MEC-1 regulated by LEF-1 expression. Yao QM; Li PP; Liang SM; Lu K; Zhu XJ; Liu YX; Zhang F; Yuan T; Wang X Int J Clin Exp Pathol; 2015; 8(7):7921-8. PubMed ID: 26339357 [TBL] [Abstract][Full Text] [Related]
4. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia. Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084 [TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin gene rearrangements and mutational status in argentinian patients with chronic lymphocytic leukemia. Stanganelli C; Travella A; Bezares R; Slavutsky I Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):447-457.e2. PubMed ID: 23665144 [TBL] [Abstract][Full Text] [Related]
6. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment. Morabito F; Cutrona G; Mosca L; D'Anca M; Matis S; Gentile M; Vigna E; Colombo M; Recchia AG; Bossio S; De Stefano L; Maura F; Manzoni M; Ilariucci F; Consoli U; Vincelli I; Musolino C; Cortelezzi A; Molica S; Ferrarini M; Neri A Leuk Res; 2015 Aug; 39(8):840-5. PubMed ID: 26038121 [TBL] [Abstract][Full Text] [Related]
7. Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. Bomben R; Dal-Bo M; Benedetti D; Capello D; Forconi F; Marconi D; Bertoni F; Maffei R; Laurenti L; Rossi D; Del Principe MI; Luciano F; Sozzi E; Cattarossi I; Zucchetto A; Rossi FM; Bulian P; Zucca E; Nicoloso MS; Degan M; Marasca R; Efremov DG; Del Poeta G; Gaidano G; Gattei V Clin Cancer Res; 2010 Jan; 16(2):620-8. PubMed ID: 20068100 [TBL] [Abstract][Full Text] [Related]
8. Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia. Memarian A; Hojjat-Farsangi M; Asgarian-Omran H; Younesi V; Jeddi-Tehrani M; Sharifian RA; Khoshnoodi J; Razavi SM; Rabbani H; Shokri F Leuk Lymphoma; 2009 Dec; 50(12):2061-70. PubMed ID: 19863181 [TBL] [Abstract][Full Text] [Related]
9. Blockage of Wnt/β-Catenin Signaling by Nanoparticles Reduces Survival and Proliferation of CLL Cells In Vitro-Preliminary Study. Franiak-Pietryga I; Maciejewski H; Ziemba B; Appelhans D; Voit B; Robak T; Jander M; Treliński J; Bryszewska M; Borowiec M Macromol Biosci; 2017 Nov; 17(11):. PubMed ID: 28762636 [TBL] [Abstract][Full Text] [Related]
10. Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia. Janovska P; Poppova L; Plevova K; Plesingerova H; Behal M; Kaucka M; Ovesna P; Hlozkova M; Borsky M; Stehlikova O; Brychtova Y; Doubek M; Machalova M; Baskar S; Kozubik A; Pospisilova S; Pavlova S; Bryja V Clin Cancer Res; 2016 Jan; 22(2):459-69. PubMed ID: 26240275 [TBL] [Abstract][Full Text] [Related]
11. CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): comparison of three approaches to analyze its expression. Boonstra JG; van Lom K; Langerak AW; Graveland WJ; Valk PJ; Kraan J; van 't Veer MB; Gratama JW Cytometry B Clin Cytom; 2006 May; 70(3):136-41. PubMed ID: 16568475 [TBL] [Abstract][Full Text] [Related]
12. Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of Poppova L; Pavlova S; Gonzalez B; Kotaskova J; Plevova K; Dumbovic G; Janovska P; Bystry V; Panovska A; Bezdekova L; Maslejova S; Brychtova Y; Doubek M; Krzyzankova M; Borsky M; Mayer J; Bryja V; Alonso S; Pospisilova S Epigenetics; 2022 Dec; 17(12):1628-1635. PubMed ID: 35333703 [TBL] [Abstract][Full Text] [Related]
14. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities. Mittal AK; Hegde GV; Aoun P; Bociek RG; Dave BJ; Joshi AD; Sanger WG; Weisenburger DD; Joshi SS Int J Mol Med; 2007 Oct; 20(4):461-9. PubMed ID: 17786276 [TBL] [Abstract][Full Text] [Related]
15. Metadherin contributes to the pathogenesis of chronic lymphocytic leukemia partially through Wnt/β-catenin pathway. Li PP; Feng LL; Chen N; Ge XL; Lv X; Lu K; Ding M; Yuan D; Wang X Med Oncol; 2015 Feb; 32(2):479. PubMed ID: 25575438 [TBL] [Abstract][Full Text] [Related]
16. Wnt/β-catenin/LEF-1 signaling in chronic lymphocytic leukemia (CLL): a target for current and potential therapeutic options. Gandhirajan RK; Poll-Wolbeck SJ; Gehrke I; Kreuzer KA Curr Cancer Drug Targets; 2010 Nov; 10(7):716-27. PubMed ID: 20578984 [TBL] [Abstract][Full Text] [Related]
17. Circular RNA circ-CBFB promotes proliferation and inhibits apoptosis in chronic lymphocytic leukemia through regulating miR-607/FZD3/Wnt/β-catenin pathway. Xia L; Wu L; Bao J; Li Q; Chen X; Xia H; Xia R Biochem Biophys Res Commun; 2018 Sep; 503(1):385-390. PubMed ID: 29902450 [TBL] [Abstract][Full Text] [Related]
18. B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage. Dal-Bo M; Del Giudice I; Bomben R; Capello D; Bertoni F; Forconi F; Laurenti L; Rossi D; Zucchetto A; Pozzato G; Marasca R; Efremov DG; Guarini A; Del Poeta G; Foà R; Gaidano G; Gattei V Br J Haematol; 2011 Apr; 153(1):3-14. PubMed ID: 21303354 [TBL] [Abstract][Full Text] [Related]
19. CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. Strati P; Parikh SA; Chaffee KG; Achenbach SJ; Slager SL; Call TG; Ding W; Jelinek DF; Hanson CA; Kay NE; Shanafelt TD Br J Haematol; 2017 Jul; 178(1):99-105. PubMed ID: 28386906 [TBL] [Abstract][Full Text] [Related]
20. Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia. Mangolini M; Götte F; Moore A; Ammon T; Oelsner M; Lutzny-Geier G; Klein-Hitpass L; Williamson JC; Lehner PJ; Dürig J; Möllmann M; Rásó-Barnett L; Hughes K; Santoro A; Méndez-Ferrer S; Oostendorp RAJ; Zimber-Strobl U; Peschel C; Hodson DJ; Schmidt-Supprian M; Ringshausen I Nat Commun; 2018 Sep; 9(1):3839. PubMed ID: 30242258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]